October 13, 2018

ASRT: Assertio Holdings, Inc. Stock

by Wilton Risenhoover

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M)	92.07
Enterprise Value ($M)	92.92
Book Value ($M)	130.52
Book Value / Share	1.37
Price / Book	0.71
NCAV ($M)	35.67
NCAV / Share	0.37
Price / NCAV	2.58

Profitability (mra)
Return on Invested Capital (ROIC)	-0.40
Return on Assets (ROA)	-0.18
Return on Equity (ROE)	-0.36

Liquidity (mrq)
Quick Ratio	1.57
Current Ratio	2.01

Balance Sheet (mrq) ($M)
Current Assets	181.16
Assets	276.00
Liabilities	145.48
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	0.00
Operating Income	0.00
Net Income	0.00
Earnings Per Share Basic And Diluted	n/a
Earnings Per Share Diluted	n/a
Earnings Per Share Basic	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	0.00
Cash from Investing	0.00
Cash from Financing	0.00
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
11-14	13G/A	Armistice Capital, Llc	0.00	-100.00
11-12	13G/A	Vanguard Group Inc	4.68	0.00
07-08	13G/A	BlackRock, Inc.	1.50	-78.92
02-14	13G/A	Continental General Insurance Co	0.00	-100.00
02-14	13G	Nantahala Capital Management, LLC	8.00

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2024-11-12	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-07	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-06	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-11	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2024-11-22	343,111	554,629	61.86
2024-11-21	129,643	566,631	22.88
2024-11-20	76,298	319,182	23.90
2024-11-19	304,820	1,937,671	15.73
2024-11-18	197,583	652,380	30.29
(click for more detail)

Similar Companies
APVO – Aptevo Therapeutics Inc.	ARTL – Artelo Biosciences, Inc.
ASNS – Actelis Networks, Inc.	ATNF – 180 Life Sciences Corp.
ATOS – Atossa Therapeutics, Inc.

Financial data and stock pages provided by
Fintel.io

Related